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Bepridil hydrochloride is a multiple ion channel blocker with relatively strong suppressive
eﬀects for various Kþ channels. Recent clinical studies mainly done in Japan have revealed
the eﬃcacy of the agent for the management of atrial ﬁbrillation (AF). The pharmacological
conversion eﬀect for persistent AF seems particularly promising. The agent also has robust
eﬀects in maintaining sinus rhythm after pharmacological or electrical conversion, as well as
suppressing recurrent attacks of paroxysmal AF. Though torsades de pointes may develop due
to QT prolongation, an appropriate dosage and careful follow-up can prevent this serious
complication. Now that the antiarrhythmic eﬃcacy of bepridil for AF is recognized in Japan,
the agent is poised to resurface on the world stage as a treatment for AF.
(J Arrhythmia 2009; 25: 4–9)
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Introduction
Bepridil hydrochloride is an anti-anginal drug
classiﬁed as a calcium channel blocker.1,2) The agent
blocks multiple ion channels, including sodium and
potassium channels.3,4) Its potassium-channel-block-
ing action is relatively strong, and Class III anti-
arrhythmic eﬀects akin to those of amiodarone are
expected for various arrhythmias. Yet soon after the
introduction of bepridil, the Kþ channel blocking
action of the agent and relatively large doses
required (even for Western patients) reportedly led
to a high incidence of QT prolongation following
torsades de pointes (TdP).5) As a consequence, the
agent was withdrawn from the commercial market in
the West almost 20 years ago. Meanwhile, bepridil
was approved as an antiarrhythmic drug in Japan.
Over the last decades, Japanese arrhythmologists
have accumulated therapeutic experience with the
agent mostly for the treatment of atrial ﬁbrillation
(AF), with good data on dosing.6–9) Though only a
few clinical studies have been conducted so far,
bepridil has resurfaced as an eﬀective drug for AF.
In this review we describe the clinical eﬃcacy and
safety of bepridil with a focus on the treatment of
AF.
Eﬃcacy for persistent and paroxysmal AF
Persistent AF is usually deﬁned as a ﬁbrillation of
the atrium which lasts for more than 7 days and
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requires electrical or pharmacological conversion
to sinus rhythm. Spontaneous conversion to sinus
rhythm is very diﬃcult for persistent AF.10) To cure
the condition, cardiologists schedule pharmacolog-
ical or intentional electrical cardioversion under
appropriate anticoagulation therapy. In administer-
ing pharmacological conversion, the eﬃcacy of class
Ia and Ic drugs declines when the AF lasts for long
periods. Worse still, persistent atrial ﬂutter and
adverse eﬀects may develop in patients treated with
these drugs. Class III drugs may be eﬀective from
the standpoint of cardioversion, but the results are
not always favorable. Kochiadakis, et al compared
the conversion to sinus rhythm between amiodarone
and propafenone in patients with chronic AF (lasting
for more than 3 weeks).11) Conversion was achieved
in 16 of 34 (47%) patients treated by amiodarone
versus 13 of 32 (40.6%) patients treated by prop-
afenone. These ﬁndings were inconclusive, however,
as the patient populations were too small. In the
SAFE-T study, 665 patients with persistent AF were
randomly assigned to 3 groups treated respectively
with amiodarone (267), sotalol (261), and placebo
(137). After administration for 28 days, spontaneous
conversion was obtained in 27.1% of patients in the
amiodarone group, 24.2% of patients in the sotalol
group, and 0.8% of patients treated with placebo.12)
These results indicated that even the class III drugs
were incapable of achieving conversion to sinus
rhythm in more than 30% of patients with long-
lasting AF. Are there any drugs capable of confer-
ring higher conversion eﬀects? It may be that
bepridil, an agent used mainly in Japan, does just
that. Our group has already reported the preliminary
results with sinus rhythm conversion and mainte-
nance eﬀects of bepridil for persistent AF.7) Though
this was a non-randomized retrospective study, it
provides the only published data on the eﬃcacy of
bepridil for a relatively large population of patients
with persistent AF.13)
Bepridil was administered to 170 patients with
persistent AF (83 males). The average age was 58
years and the mean duration of AF was 3.3 months.
Underlying heart disease, including hypertension
and ischemic heart disease, was observed in 70
patients. The mean left ventricular ejection fraction
(EF) was 64% and left atrial dimension (LAD) was
40mm. Bepridil was administered starting from
100mg daily and increased up to a maximum of
200mg. Concomitant anti-coagulation therapy and
rate control drugs such as digitalis, -blockers, or
calcium antagonists were used when necessary.
Sinus rhythm was restored in 98 of 170 patients
(58%), with a mean conversion time of 2.2 months
(Figure 1). Most of these 98 patients experienced
sinus rhythm conversion within 3 months, and 86
(78%) have maintained sinus rhythm for an average
follow-up of 20 months. Thirty-four of 72 patients
who failed to achieve pharmacological conversion
to sinus rhythm underwent DC cardioversion. DC
cardioversion restored sinus rhythm in 21 patients,
and sinus rhythm was maintained in 18 (86%) of
these patients over an average follow-up of 20
months.
A few earlier studies have investigated persistent
AF using bepridil. Perelman et al compared the
eﬀects of amiodarone and bepridil in 14 patients
with chronic AF.5) The conversion rate to sinus
rhythm was 4 of 10 patients (40%) with amiodarone
and 9 of 14 patients (64%) with bepridil. In a study
with a fairly small population, Fujiki et al6) observed
that bepridil alone or in combination with aprindine
restored sinus rhythm in 69% of 32 patients with
persistent AF. Imai et al reported that a combination
of bepridil and class Ic antiarrhythmic drugs was
eﬀective for conversion to sinus rhythm. In 32 cases
of persistent AF refractory to class I antiarrhythmic
drugs, 9 patients were restored to sinus rhythm by
bepridil alone. When the other 23 without conver-
sion to sinus rhythm were treated with a combination
72
Conversion to SR Maintenance of SR
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12
Follow-up:
Average 20 months
Time to conversion:
2.2 months
DC
34
N=170
98
(58%)Figure 1 Clinical eﬃcacy of bepridil in
patients with persistent AF.
In 170 patients with persistent AF, 98 (58%)
patients could be converted to sinus rhythm
(SR) by bepridil with a mean conversion time
of 2.2 months. After successful conversion
to SR, 86 of 98 (78%) patients have been
maintained in SR during a mean follow-up of
20 months.
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of bepridil and class Ic drugs, sinus rhythm was
restored in 22 (96%) patients. Though these studies
investigated bepridil in combination with class I
drugs, and only in small patient populations, they
suggest that bepridil is eﬀective to some degree in
converting persistent AF to sinus rhythm.
Bepridil requires a somewhat longer interval for
conversion, as it acts slowly in bringing about a
steady serum concentration. In our study, the mean
interval to conversion was 2.2 months. One of the
mechanisms of late conversion is the reverse-
remodeling eﬀect brought by T-type Ca2þ blocking
action. The eﬀect of T-type Ca2þ channel blocking
in preventing the mid to late phase of atrial
remodeling has been explained.14) Morphological
changes were observed in the ﬁbrillatory waves of
the patients in whom bepridil restored sinus rhythm:
the ﬁbrillation waves were initially ﬁne and of low
amplitude, and thereafter they gradually became
larger and more organized until just before the sinus
rhythm was restored. Fujiki et al compared the
interval of the ﬁbrillation cycle length (FCL) using
spectral analyses before and after bepridil.15) They
noted a greater increase of FCL in responders, and
the ﬁbrillation waves coarsened somewhat before
termination. In one of our earlier studies, the
ﬁbrillatory wave morphology changed from small
and ﬁne to coarse and large before sinus restora-
tion.7)
Recommendable approach for persistent AF
Based on these clinical experiences, we recom-
mend the following approach for persistent AF
(Figure 2). If patient has long-lasting AF (<1 year),
commence bepridil under appropriate anticoagula-
tion therapy. Add rate control drugs and upstream
therapy, including angiotensin converting enzyme
inhibitor, angiotensin II receptor blocker, and statins,
if necessary. If sinus conversion is obtained within
3 months, continue the bepridil therapy. If sinus
conversion is not obtained, schedule DC cardiover-
sion as the next step. This approach can be expected
to bring about sinus conversion in more than 50% of
patients with persistent AF.
Clinical data on the long-term eﬃcacy of sinus
rhythm maintenance by bepridil is scanty. In a study
by Imai et al on 32 cases of persistent AF, bepridil
alone restored sinus rhythm in 9 patients and
maintained it in 8.9) In patients administered bepridil
in combination with class Ic drugs, sinus rhythm was
maintained in all of the restored patients (96%) over
an average follow-up of 14 months. In our study
with 98 patients in whom sinus rhythm had been
pharmacologically restored by bepridil, sinus rhythm
was maintained in 86 (78%) of the patients over an
average follow-up of 20 months.13) In a prospective,
multi-center trial reported by Roy et al, AF recurred
after a mean follow-up of 16 months in 71 of 201
(35%) patients treated with amiodarone and 127 of
201 patients (63%) treated with sotalol or propafe-
none.16) In SAFE-T, a comparison of sinus rhythm
maintenance in patients treated with amiodarone,
sotalol, or placebo over a much longer period,
amiodarone maintained sinus rhythm in 50% of the
patients who received it over a follow-up of almost
30 months.12) Amiodarone is superior to sotalol and
placebo, but not always eﬀective in preventing
recurrence over in the long term. In this regard,
bepridil seems to have a comparable eﬀect to
amiodarone for maintaining sinus rhythm. Further
investigation will be required to clarify this issue.
Recent basic studies seem to add evidence in
support of the eﬃcacies of bepridil. Bepridil blocks
not only slow components of the multiple Kþ
currents,3,4,17,18) but also the ultra rapid (Ik-ur) K
þ
Electrical
Conversion
Continue
Medication
Ventricular rate control
Anti-thrombotic therapy
Bepridil
β-blocker, digitalis, verapamil
Warfarin, Aspirin
100-200mg /day
3 months observation
No
Conversion to
Sinus Rhythm
Yes
Figure 2 Therapeutic protocol for persis-
tent AF.
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current. Ik-ur is only seen in the atrium, and the
eﬃcacy of bepridil for AF might be explained by this
eﬀect. Bepridil may prevent the recurrence of
paroxysmal AF via a conﬁrmed eﬀect in inhibiting
the human Kv1.5 channel current related to Ik-ur.
19)
When Yoshida et al compared the eﬃcacy of class Ic
drugs and bepridil for preventing paroxysmal AF,
they found that the eﬃcacy of bepridil for parox-
ysmal AF was attributable to a class III antiarrhyth-
mic action with relatively short f-f intervals (small
excitable-gap).20) Bepridil appears not only to re-
verse the eﬀects for mid- to long-term remodeling,
but also to suppress short-term remodeling, in the
atrium.
Adverse eﬀects of bepridil
Despite the eﬃcacy of bepridil for AF, previous
reports warned that the relatively strong potassium
channel blocking eﬀects often render TdP due to QT
prolongation. Perelman et al concluded that, in light
of the high rate of ventricular arrhythmias such as
TdP, the risks of bepridil outweigh the beneﬁts.5) We
note, however, that the dose of bepridil ranged from
200mg to 600mg in their study. This relatively high
dose of bepridil surely increased the incidence of
serious ventricular arrhythmias in their subjects.
Coumel summarized the French experience on the
safety of bepridil by gathering data on the incidence
of TdP. TdP incidence increased in a subgroup of
elderly women with hypokalemia induced by diu-
retics.21) According to post-marketing surveillance
from 1981 to 1989, a total of 108 episodes of TdP
were observed. Signiﬁcantly, however, most of the
patients who developed TdP had been receiving
relatively high doses of bepridil (318 40mg/day).
In the Japanese experience, Yasuda et al reported a
0.9% (4 of 459 patients) incidence of TdP in a
relatively large population of elderly patients with
AF or atrial ﬂutter (AFL), hypokalemia, bradycardia,
and prolonged QT intervals.22) These patients re-
ceived an average bepridil dose of 150 41mg/day.
The risk of TdP should always be considered during
administration of bepridil even under careful obser-
vation, and even at doses of less than 200mg/day.
Thus, we have proposed that the maximum dose of
bepridil should be 200mg/day.
Pulmonary ﬁbrosis is reported as a rare but
serious complication during bepridil administration.
Vasilomanolakis et al reported an autopsy ﬁnding
of death by bepridil-induced pulmonary ﬁbrosis in
one case. Autopsy specimens of lung tissue indicated
strong ﬁbrotic interstitial changes. They concluded
that these changes were an adverse complication of
bepridil.23) Sekita et al reported a similar case that
could be saved by steroid pulse therapy.24) Though
the precise mechanism of pulmonary ﬁbrosis is
still unknown, similar case reports are sporadically
seen.25,26) We experienced two patients who devel-
oped pulmonary ﬁbrosis after bepridil administra-
tion, out of the over 1,000 patients we treated.
Though its cause remains elusive, this complication
should be always kept in mind.
Indication for patients with LV dysfunction
Because of its class III eﬀect, bepridil can also be
applied in patients with left ventricular (LV) dys-
function. Bepridil basically acts as a calcium channel
blocker and weak sodium channel blocker. This
explains why its cardio-suppressive eﬀect is rela-
tively small and controversial. According to a study
on the hemodynamic eﬀects of intravenous bepridil
in patients with depressed LV function with ejection
fractions (EFs) of 0.45 or less, Josephson et al found
bepridil to exert signiﬁcant negative eﬀects in the
patients with depressed LV function.27) De Marco
et al, on the other hand, reported no deleterious
eﬀect of oral bepridil on cardiac performance in
patients with reduced LV function.28) In fact, there is
no available clinical data as to whether oral bepridil
can be used in patients with depressed LV function.
We studied the safety and eﬃcacy of bepridil in
patients with LV dysfunction retrospectively. In 481
patients with paroxysmal AF and persistent AF
treated with bepridil, we compared 22 patients with
EF < 40% (group L) and 459 patients with
EF > 40% (group N) (Table). In group L, bepridil
was started at a dose of 50mg/day, and increased to
a maximum of 200mg/day when necessary. The
average EF was 32% in group L and 66% in group
N. In persistent AF, the sinus conversion eﬀect was
50% in group L and 57% in group N. The sinus
rhythm maintenance eﬀect during the 20-month
follow-up was 57% in group L and 62% in group N.
In paroxysmal AF, group L and group N had no-
recurrence rates of 80% and 74%, respectively.
Thus, the conversion and maintenance eﬀect of sinus
rhythm did not signiﬁcantly diﬀer between these two
groups. ECG parameters with QT interval, QTc, and
QRS width showed no signiﬁcant changes from
before to after the bepridil administration. Interest-
ingly enough, adverse eﬀects were seen in 19
patients in group N versus no patients in group L.
This result could be explained by our very selective
and careful use of bepridil for this population of
patients with LV dysfunction. Again, the initial
doses were small and the subsequent dosing was
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maintained at less than 200mg/day. The patients
were examined in frequent follow-ups with ECG
recording, electrolyte check, and clinical examina-
tions. On the basis of our ﬁnding from this study, we
think it is feasible to use bepridil in patients with
deteriorated LV function, as long as we do so with
caution.
Implications for the safe use of bepridil
Through our clinical experience, we have deter-
mined several points to bear in mind regarding the
use of bepridil as an antiarrhythmic drug: 1) the
maximum dose should be kept within 200mg/day.
Physicians should be especially cautious when
administering the drug to 2) elderly and female
patients, and patients with 3) hypokalemia, 4)
bradycardia, 5) prolonged QT interval before admin-
istration, and 6) LV dysfunction. We also recom-
mend weekly monitoring of the QT interval, heart
rate on ECG, and electrolytes during the ﬁrst month
after starting the bepridil administration. Other
precipitating factors, which inﬂuence the QT inter-
val, should also be watched.
Conclusion
Bepridil shows favorable eﬃcacy in obtaining AF
conversion and sinus maintenance for patients with
persistent AF. It also appears to be useful for
preventing attacks in patients with paroxysmal AF.
Though TdP due to bepridil-induced QT prolonga-
tion is a concern, bepridil may be applied even in
patients with impaired LV function. Now that the
antiarrhythmic eﬃcacy of bepridil for AF is recog-
nized in Japan, the agent is poised to resurface on the
world stage as a treatment for AF.
References
1) Harder DR, Spelerakis N: Bepridil blockade of Ca2þ-
dependent action potentials in vascular muscle of dog
coronary artery. J Cardiovasc Pharmac 1981; 3: 906–914
2) DiBianco R, Alpert J, Katz RJ, Spann J, Chesler E, Ferri
DP, Larca LJ, Costello RB, Gore JM, Eisenman MJ,
Cockrell JL, Pauls JF: Bepridil for chronic stable angina
pectoris: results of a prospective multi-center, placebo
controlled, dose-ranging study in 77 patients. Am J
Cardiol 1984; 53: 35–41
3) Anno T, Furuta T, Itoh M, Kodma I, Toyama J, Yamada
K: Eﬀects of bepridil on the electrophysiological proper-
ties of guinea-pig ventricular muscles. Br J Pharmac
1984; 81: 41–47
4) Wang JC, Kiyosue T, Kiriyama K, Arita M: Bepridil
diﬀerently inhibits two delayed rectiﬁer Kþ currents, Ikr
and Iks, in guinea-pig ventricular myocytes. Br J
Pharmac 1999; 128: 1733–1738
5) Perelman MS, McKenna WJ, Rowland E, Krikler DM: A
comparison of bepridil with amiodarone in the treatment
of established atrial ﬁbrillation. Br Heart J 1987; 58:
339–344
6) Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H:
Usefulness and safety of bepridil in converting persistent
atrial ﬁbrillation to sinus rhythm. Am J Cardiol 2003; 92:
472–475
7) Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y,
Nakazato K, Tokano T, Mineda Y, Sumiyoshi M, Nakata
Y, Daida H: Conversion and maintenance of sinus
rhythm by bepridil in patients with persistent atrial
ﬁbrillation. Circ J 2005; 69: 44–48
8) Miyaji K, Tada H, Fukushima K, Hashimoto T, Kaseno
K, Hiramatsu S, Tadokoro K, Naito S, Nakamura K,
Oshima S, Taniguchi K, Ohe T: Eﬃcacy and safety of
the additional bepridil treatment in patients with atrial
ﬁbrillation refractory to class I antiarrhythmic drugs.
Circ J 2007; 71: 1250–1257
9) Imai S, Saito F, Takase H, Enomoto M, Aoyama H,
Table Safety and eﬃcacy of bepridil for AF between normal
and impaired LV function
Group N (n ¼ 459) L (n ¼ 22)
Background
Age 62 12 65 11
EF (%) 66 8 32 7
LAD (mm) 39 6 46 7
Dose (mg/day) 165 37 159 40
ACE-I/ARB 152 (33%) 10 (46%)
-blocker 117 (26%) 6 (27%)
Persistent AF n ¼ 198 n ¼ 17
Conversion rate 113 (57%) 9 (53%)
SR maintenance rate 89 (79%) 6 (75%)
Mean F/U (months) 20.1 20
Paroxysmal AF n ¼ 261 n ¼ 5
No recurrence 192 (74%) 4 (80%)
Mean F/U (months) 20.7 14.9
ECG parametes in Group L Before After
QT 0.40  0.05 0.42  0.56
QTc 0.44  0.05 0.45  0.04
QRS 0.10  0.01 0.10  0.01
Adverse complications
Bradycardia 4 0
Fatigue 1 0
Dizziness 1 0
QT > 0.55
Tdp (+) 4 0
Tdp () 9 0
EF: ejection fraction, LAD: left atrial dimension, ACE-I:
angiotensin converting enzyme inhibitor, ARB: angioten-
sin II recepter blocker, SR: sinus rhythm, F/U: follow-up,
Tdp: torsade de pointes  p < 0:01
J Arrhythmia Vol 25 No 1 2009
8
Yamaji S, Yokoyama K, Yagi H, Kushiro T, Hirayama
A: Use of bepridil in combination with Ic antiarrhythmic
agent in converting persistent atrial ﬁbrillation to sinus
rhythm. Circ J 2008; 72: 709–715
10) ACC/AHA/ESC2006Guidelines for the management of
patients with atrial ﬁbrillation: a report of the American
College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the European Heart
Rhythm Society of Cardiology Committee for Practice
Guidelines developed in collaboration with the European
Heart Rhythm Association and the Heart Rhythm
Society. Circulation 2006; 114: e257–354
11) Kochiadakis GE, Igoumenidis NE, Parthenakis FI,
Chlouverakis GI, Vardas PE: Amiodarone versus prop-
afenone for conversion of chronic atrial ﬁbrillation:
results of a randomized controlled study. J Am Coll
Cardiol 1999; 33: 966–971
12) Singh BN, et al: Sotalol Amiodarone Atrial Fibrillation
Eﬃcacy Trial (SAFE-T) Investigators. Amiodarone
versus sotalol for atrial ﬁbrillation. N Engl J Med
2005; 352: 1861
13) Kawano Y, Nakazato Y: Anti-arrhythmic agent for
persistent atrial ﬁbrillation. Cardioangiology 2008; 63:
239–244. (In Japanese)
14) Fareh S, Be´nardeau A, Thibault B, Nattel S: The T-type
Ca2þ channel blocker mibefradil prevents the develop-
ment of substrate for atrial ﬁbrillation by tachycardia-
induced atrial remodeling in dogs. Circulation 1999; 100:
2191–2197
15) Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H:
Usefulness and safety of bepridil in converting persistent
atrial ﬁbrillation to sinus rhythm. Am J Cardiol 2003; 92:
472–475
16) Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ,
Green M, Kus T, Lambert J, Dubuc M, Gagne´ P, Nattel
S, Thibault B: Amiodarone to prevent recurrence of atrial
ﬁbrillation. N Engl J Med 2000; 342: 913–920
17) Hara Y, Nakaya H: SD-3212, a new class I and IV
antiarrhythmic drug: a potent inhibitor of the muscarinic
acetylcholine-receptor-operated potassium current in pig
atrial cells. Br J Pharmacolo 1995; 116: 2750–2756
18) Li Y, Sato T, Arita M: Bepridil blunts the shortening of
action potential duration caused by metabolic inhibition
via blockade of ATP-sensitive Kþ Channels and Naþ-
activated Kþ Channels. J Pharmacol Exp The, 1999; 291:
562–568
19) Kobayashi S, Reien Y, Ogura T, Saito T, Masuda Y,
Nakaya H: Inhibitory eﬀect of bepridil on hKv1.5
channel current: comparison with amiodarone and
E-4031. Eur J Pharmacol 2001; 430: 149–157
20) Yoshida T, Niwano S, Inuo K, Saito J, Kojima J,
Murakami K, Hara H, Izumi T: Bepridil prevents
paroxysmal atrial ﬁbrillation by a class III antiarrhythmic
drug eﬀect. PACE 2003; 26[Pt.II]: 314–417
21) Coumel P: Safety of bepridil: from review of the
European data. Am J Cardiol 1992; 69: 75D–78D
22) Yasuda M, Nakazato Y, Saski A, Kawano Y, Nakazato
K, Tokano T, Daida H: Clinical evaluation of adverse
eﬀects during bepridil administration for atrial ﬁbrilla-
tion and ﬂutter. Circ J 2006; 70: 662–666
23) Vasilomanolakis EC, Goldberg NM: Bepridil-induced
pulmonary ﬁbrosis. Am Heart J, 1993; 126: 1016–1017
24) Gaku S, Naoshi K, Teruhiko A: A case of bepridil
induced interstitial pneumonia. Heart 2003; 89: 1415
25) Okubo F, Ando M, Ashihara Y, Okubo T, Nishitake T,
Ito T, Matsuno O, Fukami T, Miyazaki E, Kumamoto T:
A case of drug-induced pneumonitis due to bepridil.
Nihon Kokyuki Gakkai Zasshi, 2006; 44: 17–21. (In
Japanese)
26) Watanabe M, Takata Y, Fukasawa S, Sakota K, Abe T,
Goseki Y, Setoguchi Y, Chikamori T, Yamashina A:
Two patients with bepridil-induced interstitial pneumo-
nia. Circ J, in press
27) Josesphson MA, Mody T, Coyle K, Singh BN: Eﬀects on
hemodynamics and left ventricular ejection fraction of
intravenous bepridil for impaired left ventricular function
secondary to coronary artery disease. Am J Cardiol,
1987; 60: 44–49
28) De Marco T, Deedwania P, Chatterjee K: Systemic and
coronary hemodynamic eﬀects of bepridil in patients
with depressed left ventricular function. Am J Cardiol
1992; 69: 31D–36D
Nakazato Y Bepridil for atrial ﬁbrillation
9
